CCO Independent Conference Coverage of the 2022 ESMO Annual Meeting*

Exploratory analyses from CheckMate 274 show that pretreatment tumor and immune features were positively correlated with DFS in patients with high-risk muscle-invasive UC receiving adjuvant nivolumab following radical resection.

The 7-year follow-up from SOLO-1 shows continued survival benefit for patients with newly diagnosed advanced ovarian cancer who were treated with maintenance olaparib for up to 2 years vs placebo.

Retrospective analyses from the CheckMate 915 study showed that ctDNA positivity and other translational factors at baseline were associated with a worse RFS in patients with resected stage IIIB-D/IV melanoma who received adjuvant nivolumab with or without ipilimumab.

Results from the phase II/III RELATIVITY-047 trial showed improvements in response rates and durable responses with the addition of relatlimab to nivolumab vs nivolumab alone in patients with previously untreated metastatic or unresectable melanoma.

In CodeBreaK 200, sotorasib significantly increased progression-free survival and ORR vs docetaxel in patients with previously treated KRAS G12C–mutated advanced non-small-cell lung cancer.

RLY-4008, a selective FGFR2 inhibitor, showed promising efficacy and safety in patients with FGFR inhibitor–naive cholangiocarcinoma with FGFR2 fusion or rearrangement in the phase I/II ReFocus trial.

First results from the BELLINI trial evaluating the combination of nivolumab + ipilimumab before the start of neoadjuvant chemotherapy or surgery show promise in early TNBC with TILs.

Interim results from the phase III MONARCH 3 study showed a nonsignificant improvement in OS with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in patients with HR+/HER2- advanced or metastatic breast cancer.

Final OS data for the PAOLA-1 trial support the addition of olaparib to bevacizumab for patients with HRD-positive ovarian cancer receiving treatment in the frontline setting.

Primary results from the phase III LEAP-002 study showed that first-line treatment with lenvatinib plus pembrolizumab was not superior to lenvatinib plus placebo in patients with advanced hepatocellular carcinoma.

In the phase III CheckMate 914 study, 6 months of adjuvant nivolumab plus ipilimumab following nephrectomy did not improve disease-free survival vs placebo in patients with stage II/III clear-cell RCC at high risk of recurrence.

Updated results from the phase III ADAURA trial showed a clinically meaningful improvement in DFS with adjuvant osimertinib vs placebo in fully resected stage IB-IIIA EGFR-mutated NSCLC.

Results from a post hoc analysis of the CheckMate 816 study showed improved pathologic complete response and EFS with neoadjuvant nivolumab plus platinum-doublet CT in patients with resectable NSCLC regardless of lymph node involvement.

Interim analyses from the phase II DESTINY-Lung02 trial showed clinically meaningful responses and no new safety concerns with T-DXd 5.4 mg/kg in patients with HER2-mutant NSCLC who had received at least 1 previous line of therapy.

Neoadjuvant therapy with pembrolizumab significantly improved event-free survival compared with pembrolizumab as adjuvant therapy in patients with resectable stage III-IV melanoma.

Results from cohort K of the phase I/II EV-103 study evaluating enfortumab vedotin with or without pembrolizumab as first-line treatment in patients with advanced or metastatic UC who are ineligible for cisplatin showed promising efficacy and a manageable safety profile.

Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.

Results from the phase III COSMIC-313 study showed that PFS was significantly improved with the addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC.